Jerry Avorn

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. pmc The validity of a rheumatoid arthritis medical records-based index of severity compared with the DAS28
    Masayo Sato
    Division of Pharmacoepidemiology, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, 1620 Tremont Street, Suite 3030, Boston, MA 02120, USA
    Arthritis Res Ther 8:R57. 2006
  2. ncbi request reprint Balancing the cost and value of medications: the dilemma facing clinicians
    Jerry Avorn
    Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital, Boston, USA
    Pharmacoeconomics 20:67-72. 2002
  3. ncbi request reprint Therapeutic delay and reduced functional status six months after thrombolysis for acute myocardial infarction
    Jerry Avorn
    Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital and Harvard Medical School, 1620 Tremont Street, Boston, MA 02120, USA
    Am J Cardiol 94:415-20. 2004
  4. ncbi request reprint Sudden uncontrollable somnolence and medication use in Parkinson disease
    Jerry Avorn
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02120, USA
    Arch Neurol 62:1242-8. 2005
  5. ncbi request reprint Comparing the costs, risks, and benefits of competing strategies for the primary prevention of venous thromboembolism
    Jerry Avorn
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, 1620 Tremont Street, Suite 3030, Boston, MA 02120, USA
    Circulation 110:IV25-32. 2004
  6. ncbi request reprint Underuse of ACE inhibitors and angiotensin II receptor blockers in elderly patients with diabetes
    Wolfgang C Winkelmayer
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    Am J Kidney Dis 46:1080-7. 2005
  7. ncbi request reprint Gaps in treatment among users of osteoporosis medications: the dynamics of noncompliance
    M Alan Brookhart
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital Harvard Medical School, Boston, Mass 02120, USA
    Am J Med 120:251-6. 2007
  8. ncbi request reprint Identification of individuals with CKD from Medicare claims data: a validation study
    Wolfgang C Winkelmayer
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02120, USA
    Am J Kidney Dis 46:225-32. 2005
  9. pmc Increasing levels of restriction in pharmacoepidemiologic database studies of elderly and comparison with randomized trial results
    Sebastian Schneeweiss
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Med Care 45:S131-42. 2007
  10. ncbi request reprint Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis
    Daniel H Solomon
    Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02120, USA
    Arthritis Rheum 54:3790-8. 2006

Collaborators

Detail Information

Publications113 found, 100 shown here

  1. pmc The validity of a rheumatoid arthritis medical records-based index of severity compared with the DAS28
    Masayo Sato
    Division of Pharmacoepidemiology, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, 1620 Tremont Street, Suite 3030, Boston, MA 02120, USA
    Arthritis Res Ther 8:R57. 2006
    ..The RARBIS has both face and convergent validity for patients with RA and relevant subgroups and may have application for medical records studies in patients with RA...
  2. ncbi request reprint Balancing the cost and value of medications: the dilemma facing clinicians
    Jerry Avorn
    Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital, Boston, USA
    Pharmacoeconomics 20:67-72. 2002
    ....
  3. ncbi request reprint Therapeutic delay and reduced functional status six months after thrombolysis for acute myocardial infarction
    Jerry Avorn
    Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital and Harvard Medical School, 1620 Tremont Street, Boston, MA 02120, USA
    Am J Cardiol 94:415-20. 2004
    ..Thus, in patients with AMI, earlier presentation to the hospital and more rapid initiation of thrombolysis could prevent significant decreases in functional status months after the initial infarct...
  4. ncbi request reprint Sudden uncontrollable somnolence and medication use in Parkinson disease
    Jerry Avorn
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02120, USA
    Arch Neurol 62:1242-8. 2005
    ....
  5. ncbi request reprint Comparing the costs, risks, and benefits of competing strategies for the primary prevention of venous thromboembolism
    Jerry Avorn
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, 1620 Tremont Street, Suite 3030, Boston, MA 02120, USA
    Circulation 110:IV25-32. 2004
    ....
  6. ncbi request reprint Underuse of ACE inhibitors and angiotensin II receptor blockers in elderly patients with diabetes
    Wolfgang C Winkelmayer
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    Am J Kidney Dis 46:1080-7. 2005
    ..However, little is known about the adequacy of adherence to these guidelines in elderly patients with diabetes and predictors of such appropriate ACE-inhibitor or ARB use...
  7. ncbi request reprint Gaps in treatment among users of osteoporosis medications: the dynamics of noncompliance
    M Alan Brookhart
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital Harvard Medical School, Boston, Mass 02120, USA
    Am J Med 120:251-6. 2007
    ..We sought to estimate the percentage of patients who restart osteoporosis therapy after a prolonged lapse in medication use and to identify the factors associated with a return to compliance...
  8. ncbi request reprint Identification of individuals with CKD from Medicare claims data: a validation study
    Wolfgang C Winkelmayer
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02120, USA
    Am J Kidney Dis 46:225-32. 2005
    ..The validity of this approach to identify patients with CKD has not been sufficiently studied...
  9. pmc Increasing levels of restriction in pharmacoepidemiologic database studies of elderly and comparison with randomized trial results
    Sebastian Schneeweiss
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Med Care 45:S131-42. 2007
    ..The goal of restricting study populations is to make patients more homogeneous regarding potential confounding factors and treatment effects and thereby achieve less biased effect estimates...
  10. ncbi request reprint Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis
    Daniel H Solomon
    Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02120, USA
    Arthritis Rheum 54:3790-8. 2006
    ..This study was undertaken to investigate the effects of various immunosuppressive medications on the risk of cardiovascular events among a group of older patients with RA...
  11. ncbi request reprint Adherence to lipid-lowering therapy and the use of preventive health services: an investigation of the healthy user effect
    M Alan Brookhart
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital Harvard Medical School, Boston, MA 02120, USA
    Am J Epidemiol 166:348-54. 2007
    ..Further work is needed to identify study design and analysis methods that can be used to minimize the healthy user bias in studies of preventive therapies...
  12. doi request reprint Improvements in long-term mortality after myocardial infarction and increased use of cardiovascular drugs after discharge: a 10-year trend analysis
    Soko Setoguchi
    Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02120, USA
    J Am Coll Cardiol 51:1247-54. 2008
    ..We sought to assess the relationship between increasing use of cardiovascular medications and trends in long-term prognosis after myocardial infarction (MI) in the elderly...
  13. pmc Tumor necrosis factor-alpha antagonist use and heart failure in elderly patients with rheumatoid arthritis
    Soko Setoguchi
    Divisions of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital and Harvard MedicalSchool, Boston, MA 02130, USA
    Am Heart J 156:336-41. 2008
    ..Although TNFAs had significant benefits in treating rheumatoid arthritis (RA), little is known whether the drugs pose an increased risk of HF in older patients with RA...
  14. ncbi request reprint Compliance with osteoporosis medications
    Daniel H Solomon
    Divisions of Pharmacoepidemiology, Brigham and Women s Hospital, Boston, MA 02120, USA
    Arch Intern Med 165:2414-9. 2005
    ..This study was undertaken to assess the level and determinants of compliance with drugs prescribed for osteoporosis...
  15. pmc Cost-effectiveness of providing full drug coverage to increase medication adherence in post-myocardial infarction Medicare beneficiaries
    Niteesh K Choudhry
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02120, USA
    Circulation 117:1261-8. 2008
    ....
  16. ncbi request reprint Relationship between COX-2 specific inhibitors and hypertension
    Daniel H Solomon
    Division of Pharmacoepidemiology, Brigham and Women s Hospital, Harvard Medical School, Boston, Mass 02120, USA
    Hypertension 44:140-5. 2004
    ..1; 95% CI, 1.0 to 4.3). In this retrospective case-control study of patients aged > or =65 years, rofecoxib use was associated with an increased relative risk of new onset hypertension; this was not seen in patients taking celecoxib...
  17. pmc Subgroup analyses to determine cardiovascular risk associated with nonsteroidal antiinflammatory drugs and coxibs in specific patient groups
    Daniel H Solomon
    Brigham and Women s Hospital, 1620 Tremont Street, Boston, MA 02120, USA
    Arthritis Rheum 59:1097-104. 2008
    ..There is substantial concern regarding the potential cardiovascular adverse effects of selective coxibs and nonselective NSAIDs, but many patients with arthritis experience important clinical benefits from these agents...
  18. ncbi request reprint Physician follow-up and provider continuity are associated with long-term medication adherence: a study of the dynamics of statin use
    M Alan Brookhart
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Mass, USA
    Arch Intern Med 167:847-52. 2007
    ....
  19. pmc Consistency of performance ranking of comorbidity adjustment scores in Canadian and U.S. utilization data
    Sebastian Schneeweiss
    Division of Pharmacoepidemiology and Pharmacoeconomics, Gigham and Women s Hospital and Harvard Medical School, Boston, MA 02120, USA
    J Gen Intern Med 19:444-50. 2004
    ..We sought to evaluate and rank the performance of comorbidity scores across selected U.S. and Canadian elderly populations using health care utilization databases...
  20. ncbi request reprint Effects of noncardiovascular comorbidities on antihypertensive use in elderly hypertensives
    Philip S Wang
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    Hypertension 46:273-9. 2005
    ..Highly prevalent, noncardiovascular conditions appear to deter use of antihypertensives in elderly with hypertension...
  21. doi request reprint Full coverage for preventive medications after myocardial infarction
    Niteesh K Choudhry
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02120, USA
    N Engl J Med 365:2088-97. 2011
    ..Adherence to medications that are prescribed after myocardial infarction is poor. Eliminating out-of-pocket costs may increase adherence and improve outcomes...
  22. pmc High-risk patients' readiness to undergo BMD testing for osteoporosis diagnosis in Pennsylvania
    Jennifer M Polinski
    Brigham and Women s Hospital, Boston, Massachusetts, USA
    Int Q Community Health Educ 29:223-40. 2008
    ..We found several correlates of readiness to undergo BMD screening that may be used to design effective interventions...
  23. ncbi request reprint Explained variation in a model of therapeutic decision making is partitioned across patient, physician, and clinic factors
    M Alan Brookhart
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital Harvard Medical School, 1620 Tremont Street, Suite 3030, Boston, MA 02120, USA
    J Clin Epidemiol 59:18-25. 2006
    ..A statistical method is presented for attributing explained variation in patient care to different levels of aggregation in a multilevel model with the aim of prioritizing and targeting quality improvement interventions...
  24. doi request reprint Patient, physician, and payment predictors of statin adherence
    David C Chan
    Department of Medicine, Division of General Internal Medicine, Brigham and Women s Hospital, Boston, MA, USA
    Med Care 48:196-202. 2010
    ..Although many patient, physician, and payment predictors of adherence have been described, knowledge of their relative strength and overall ability to explain adherence is limited...
  25. pmc Rationale and design of the Post-MI FREEE trial: a randomized evaluation of first-dollar drug coverage for post-myocardial infarction secondary preventive therapies
    Niteesh K Choudhry
    Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02120, USA
    Am Heart J 156:31-6. 2008
    ..Removing patient out-of-pocket drug costs may increase adherence, improve clinical outcomes, and even reduce overall health costs for high-risk patients. The existing data are inadequate to assess whether this strategy is effective...
  26. pmc Supplementing claims data with outpatient laboratory test results to improve confounding adjustment in effectiveness studies of lipid-lowering treatments
    Sebastian Schneeweiss
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Boston, MA 02120, USA
    BMC Med Res Methodol 12:180. 2012
    ..Adjusting for laboratory test results may result in better confounding control when added to administrative claims data in the study of treatment effects. However, missing values can arise through several mechanisms...
  27. ncbi request reprint Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records
    Yuka Kiyota
    Division of Pharmacoepidemiology and Pharmacoeconomics, Boston, Mass USA
    Am Heart J 148:99-104. 2004
    ....
  28. doi request reprint The association between statin use and outcomes potentially attributable to an unhealthy lifestyle in older adults
    Amanda R Patrick
    Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    Value Health 14:513-20. 2011
    ..To explore the "healthy user" and "healthy adherer" effects-hypothetical sources of bias thought to arise when patients who initiate and adhere to preventive therapies are more likely to engage in healthy behaviors than are other subjects...
  29. ncbi request reprint Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults
    Daniel H Solomon
    Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital, Harvard Medical School, 1620 Tremont St, Suite 3030, Boston, Mass 02120, USA
    Circulation 109:2068-73. 2004
    ..We studied the relative risk of acute myocardial infarction (AMI) among users of celecoxib, rofecoxib, and NSAIDs in Medicare beneficiaries with a comprehensive drug benefit...
  30. pmc Is there a relationship between patient beliefs or communication about generic drugs and medication utilization?
    William H Shrank
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02120, USA
    Med Care 47:319-25. 2009
    ..Insurers and policymakers strive to stimulate more cost-effective prescribing and, increasingly, are educating beneficiaries about generics...
  31. pmc Adjustments for unmeasured confounders in pharmacoepidemiologic database studies using external information
    TIL STURMER
    Divisions of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Med Care 45:S158-65. 2007
    ..Nonexperimental studies of drug effects in large automated databases can provide timely assessment of real-life drug use, but are prone to confounding by variables that are not contained in these databases and thus cannot be controlled...
  32. ncbi request reprint Risk of death in elderly users of conventional vs. atypical antipsychotic medications
    Philip S Wang
    Department of Psychiatry, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02120, USA
    N Engl J Med 353:2335-41. 2005
    ..However, the advisory did not apply to conventional antipsychotic medications; the risk of death with these older agents is not known...
  33. ncbi request reprint Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis
    Sebastian Schneeweiss
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02120, USA
    Arthritis Rheum 56:1754-64. 2007
    ..To assess the association between the initiation of anti-tumor necrosis factor alpha (anti-TNFalpha) therapy and the risk of serious bacterial infections in routine care...
  34. ncbi request reprint Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis
    Soko Setoguchi
    Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02130, USA
    Arthritis Rheum 54:2757-64. 2006
    ..This study was undertaken to estimate the association between treatment with biologic disease-modifying antirheumatic drugs (DMARDs) and development of cancer in patients with RA...
  35. ncbi request reprint The implications of choice: prescribing generic or preferred pharmaceuticals improves medication adherence for chronic conditions
    William H Shrank
    Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital and Harvard Medical School, Boston, Mass, USA
    Arch Intern Med 166:332-7. 2006
    ..We studied whether patients enrolled in such plans who receive generic or preferred brand-name agents when initiating chronic therapy were more adherent to treatment than those who received nonpreferred brand-name medications...
  36. ncbi request reprint Prescription opioid use among older adults with arthritis or low back pain
    Daniel H Solomon
    Brigham and Women s Hospital, Harvard Medical School, 1620 Tremont Street, Ste, 3030, Boston, MA 02120, USA
    Arthritis Rheum 55:35-41. 2006
    ..To examine patterns of chronic opioid use in selected groups with arthritis and low back pain and compare them with patterns among persons with ischemic heart disease...
  37. pmc Can improved prescription medication labeling influence adherence to chronic medications? An evaluation of the Target pharmacy label
    William H Shrank
    Department of Medicine, Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital, Harvard Medical School, 1620 Tremont Street Suite 3030, Boston, MA 02120, USA
    J Gen Intern Med 24:570-8. 2009
    ..A new prescription medication labeling system was implemented by Target pharmacies in May 2005 and aimed to improve readability and understanding...
  38. ncbi request reprint A propensity analysis of late versus early nephrologist referral and mortality on dialysis
    Wolfgang C Winkelmayer
    Division of Pharmacoepidemiology, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    J Am Soc Nephrol 14:486-92. 2003
    ..Further research is needed to identify patients at particular risk so that interventions to prevent early deaths on dialysis in LR patients can be developed and tested...
  39. pmc Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation
    Sebastian Schneeweiss
    Department of Medicine, Harvard Medical School, Boston, MA, USA
    Circ Cardiovasc Qual Outcomes 5:480-6. 2012
    ..We sought to compare the efficacy and safety of the 3 new agents based on data from their published warfarin-controlled randomized trials, using the method of adjusted indirect comparisons...
  40. doi request reprint Warnings without guidance: patient responses to an FDA warning about ezetimibe
    William H Shrank
    Department of Medicine, Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital, Harvard Medical School, Boston 02120, USA
    Med Care 50:479-84. 2012
    ..We investigated the proportion of patients who discontinued therapy and switched to a clinically appropriate alternative after the FDA communication...
  41. doi request reprint Patterns of medication initiation in newly diagnosed diabetes mellitus: quality and cost implications
    Nihar R Desai
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Boston, MA, USA
    Am J Med 125:302.e1-7. 2012
    ..We aimed to evaluate temporal trends in the use of specific drugs for the initial management of type 2 diabetes and to estimate the economic consequences of non-recommended care...
  42. pmc Development of a health care utilisation data-based index for rheumatoid arthritis severity: a preliminary study
    Gladys Ting
    Department of Medicine, Division of Pharmacoepidemiology, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02120, USA
    Arthritis Res Ther 10:R95. 2008
    ....
  43. doi request reprint Cost-effectiveness of genotype-guided warfarin dosing for patients with atrial fibrillation
    Amanda R Patrick
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02120, USA
    Circ Cardiovasc Qual Outcomes 2:429-36. 2009
    ..However, the effectiveness of genotyping in improving anticoagulation control and reducing major bleeding has not yet been compellingly demonstrated. Genotyping currently costs $400 to $550...
  44. pmc Treatment effects in the presence of unmeasured confounding: dealing with observations in the tails of the propensity score distribution--a simulation study
    TIL STURMER
    Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Am J Epidemiol 172:843-54. 2010
    ..Increasing validity based on PS trimming may be a unique advantage of PS's over conventional outcome models...
  45. ncbi request reprint Should patients receive secondary prevention medications for free after a myocardial infarction? An economic analysis
    Niteesh K Choudhry
    Harvard Medical School and Brigham and Women s Hospital, Boston, Massachusetts, USA
    Health Aff (Millwood) 26:186-94. 2007
    ..Our analysis suggests that covering combination therapy for such patients will save both lives and money...
  46. ncbi request reprint Assessing health state utilities in elderly patients at cardiovascular risk
    Wolfgang C Winkelmayer
    Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02120, USA
    Med Decis Making 26:247-54. 2006
    ..Health state preferences can be a crucial component of cost-effectiveness analyses, but off-the-shelf health state utilities specifically for older people are not available...
  47. ncbi request reprint Nephrologist care and mortality in patients with chronic renal insufficiency
    Jerry Avorn
    Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Arch Intern Med 162:2002-6. 2002
    ..We sought to determine whether early or frequent access to nephrologist care prior to the initiation of dialysis was associated with a difference in mortality rates in the first year after dialysis began...
  48. ncbi request reprint Prior authorization policies for selective cyclooxygenase-2 inhibitors in Medicaid: a policy review
    Michael A Fischer
    Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital, Harvard Medical School, 1620 Tremont Street, Boston, MA 02120, USA
    Med Care 44:658-63. 2006
    ..However, the evidence base for the prior authorization criteria has not been examined previously...
  49. doi request reprint NSAID switching and short-term gastrointestinal outcome rates after the withdrawal of rofecoxib
    Sebastian Schneeweiss
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, 1620 Tremont Street, Boston, MA 021205, USA
    Pharmacoepidemiol Drug Saf 18:1134-42. 2009
    ....
  50. ncbi request reprint Determinants of selective cyclooxygenase-2 inhibitor prescribing: are patient or physician characteristics more important?
    Daniel H Solomon
    Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    Am J Med 115:715-20. 2003
    ..We examined the relative effects of patient risk factors for gastrointestinal toxicity, other patient characteristics, and physician prescribing preferences on the decision to prescribe a selective COX-2 inhibitor...
  51. ncbi request reprint The medical license number accurately identifies the prescribing physician in a large pharmacy claims database
    M Alan Brookhart
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02120, USA
    Med Care 45:907-10. 2007
    ..We studied the accuracy of the medical license number in data from a state-run drug benefit plan by assessing its consistency with 2 external sources of data...
  52. pmc High-dimensional propensity score adjustment in studies of treatment effects using health care claims data
    Sebastian Schneeweiss
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    Epidemiology 20:512-22. 2009
    ..Here, we develop and test an algorithm that empirically identifies candidate covariates, prioritizes covariates, and integrates them into a propensity-score-based confounder adjustment model...
  53. pmc Rationale and design of the Study Assessing the Effect of Cardiovascular Medications Provided as Low-cost, Evidence-based Generic Samples (SAMPLES) trial
    William H Shrank
    Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA, USA
    Am Heart J 157:613-9. 2009
    ..Highly effective generic cardiovascular medications are frequently underused, leading to greater overall drug costs and cost-related nonadherence...
  54. ncbi request reprint Osteoporosis action: design of the healthy bones project trial
    Daniel H Solomon
    Division of Pharmacoepidemiology, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, 1620 Tremont Street, Suite 3030, Boston, MA, USA
    Contemp Clin Trials 26:78-94. 2005
    ..All outcomes will be analyzed using random effects models accounting for clustering of subjects within physicians' practices...
  55. ncbi request reprint Ten-year trends of cardiovascular drug use after myocardial infarction among community-dwelling persons > or =65 years of age
    Soko Setoguchi
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts, USA
    Am J Cardiol 100:1061-7. 2007
    ..The underuse of statins and BBs was marked in black patients and did not improve over time...
  56. pmc The prevalence and cost of unapproved uses of top-selling orphan drugs
    Aaron S Kesselheim
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts, United States of America
    PLoS ONE 7:e31894. 2012
    ..However, some orphan drugs become top sellers for unclear reasons. We sought to evaluate the extent and cost of approved and unapproved uses of orphan drugs with the highest unit sales...
  57. ncbi request reprint The costs and benefits of enhanced depression care to employers
    Philip S Wang
    Department of Psychiatry, Brigham and Women s Hospital, 75 Francis Street, Boston, MA, USA
    Arch Gen Psychiatry 63:1345-53. 2006
    ..Although outreach and enhanced treatment interventions improve depression outcomes, uptake has been poor in part because purchasers lack information on their return on investment...
  58. ncbi request reprint Design of cluster-randomized trials of quality improvement interventions aimed at medical care providers
    Robert J Glynn
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, and Harvard Medical School, Boston, Massachusetts, USA
    Med Care 45:S38-43. 2007
    ..Such trials are frequently embedded in health care systems with available automated records, which can be used to enhance the design of the trial...
  59. ncbi request reprint Comparing mortality of elderly patients on hemodialysis versus peritoneal dialysis: a propensity score approach
    Wolfgang C Winkelmayer
    Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    J Am Soc Nephrol 13:2353-62. 2002
    ....
  60. pmc Angiotensin inhibition after myocardial infarction: does drug class matter?
    Wolfgang C Winkelmayer
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Boston, MA 02120, USA
    J Gen Intern Med 21:1242-7. 2006
    ..Little is known about their relative use after MI in typical care settings, and about their relative effectiveness outside the clinical trial setting...
  61. ncbi request reprint The implications of therapeutic complexity on adherence to cardiovascular medications
    Niteesh K Choudhry
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Boston, MA 02120, USA
    Arch Intern Med 171:814-22. 2011
    ..Our objective was to estimate the extent of prescribing and filling complexity in patients prescribed a cardiovascular medication and to evaluate its association with adherence...
  62. ncbi request reprint How well do patients report noncompliance with antihypertensive medications?: a comparison of self-report versus filled prescriptions
    Philip S Wang
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    Pharmacoepidemiol Drug Saf 13:11-9. 2004
    ..Although self-reports are often the only means available in routine practice, their accuracy and agreement with other data sources remain questionable...
  63. ncbi request reprint Medication use patterns for osteoporosis: an assessment of guidelines, treatment rates, and quality improvement interventions
    Daniel H Solomon
    Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital, Harvard Medical School, Boston, Mass 02120, USA
    Mayo Clin Proc 80:194-202. 2005
    ..To assess current osteoporosis treatment guidelines, studies of osteoporosis treatment, and interventions to improve osteoporosis treatment...
  64. ncbi request reprint Medicaid prior-authorization programs and the use of cyclooxygenase-2 inhibitors
    Michael A Fischer
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02120, USA
    N Engl J Med 351:2187-94. 2004
    ..To control these expenses, many state Medicaid programs have implemented prior-authorization requirements before coxibs can be prescribed. We evaluated the effect of such programs on the use of coxibs by Medicaid beneficiaries...
  65. pmc A combined comorbidity score predicted mortality in elderly patients better than existing scores
    Joshua J Gagne
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, 1620 Tremont Street, Suite 3030, Boston, MA 02120, USA
    J Clin Epidemiol 64:749-59. 2011
    ..To develop and validate a single numerical comorbidity score for predicting short- and long-term mortality, by combining conditions in the Charlson and Elixhauser measures...
  66. doi request reprint At Pitney Bowes, value-based insurance design cut copayments and increased drug adherence
    Niteesh K Choudhry
    Harvard Medical School, USA
    Health Aff (Millwood) 29:1995-2001. 2010
    ..Our study thus provides an empirical basis for the use of this approach to improve the quality of health care...
  67. ncbi request reprint Pharmacogenetic testing in the clinical management of schizophrenia: a decision-analytic model
    Roy H Perlis
    Pharmacogenomics Research Program, Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    J Clin Psychopharmacol 25:427-34. 2005
    ..More consistent reporting of test parameters such as sensitivity and specificity would greatly facilitate assessment of future pharmacogenetic studies...
  68. ncbi request reprint A Medicare database review found that physician preferences increasingly outweighed patient characteristics as determinants of first-time prescriptions for COX-2 inhibitors
    Sebastian Schneeweiss
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, 1620 Tremont Street, Suite 3030, Boston, MA 02120, USA
    J Clin Epidemiol 58:98-102. 2005
    ..We sought to quantify the relative contributions of patient vs. physician factors to the decision to prescribe selective cyclooxygenase-2 (COX-2) inhibitors during the first 2 years of their availability...
  69. pmc Improved comorbidity adjustment for predicting mortality in Medicare populations
    Sebastian Schneeweiss
    Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Health Serv Res 38:1103-20. 2003
    ..To define and improve the performance of existing comorbidity scores in predicting mortality in Medicare enrollees...
  70. doi request reprint Drug warnings that can cause fits--communicating risks in a data-poor environment
    Jerry Avorn
    Harvard Medical School, and Brigham and Women s Hospital, Boston, USA
    N Engl J Med 359:991-4. 2008
  71. ncbi request reprint Torcetrapib and atorvastatin--should marketing drive the research agenda?
    Jerry Avorn
    Harvard Medical School, Boston, USA
    N Engl J Med 352:2573-6. 2005
  72. ncbi request reprint Measuring the cost-effectiveness of lipid-lowering drugs in the elderly: the outcomes research and economic analysis components of the PROSPER trial
    Jerry Avorn
    Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Control Clin Trials 23:757-73. 2002
    ....
  73. ncbi request reprint Keeping science on top in drug evaluation
    Jerry Avorn
    Harvard Medical School and Division of Pharmacoepidemiology and Pharmacoeconomics at Brigham and Women s Hospital, Boston, USA
    N Engl J Med 357:633-5. 2007
  74. doi request reprint Pharmaceutical promotion to physicians and First Amendment rights
    Aaron S Kesselheim
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, USA
    N Engl J Med 358:1727-32. 2008
  75. ncbi request reprint Economic consequences of routine coronary angiography in low- and intermediate-risk patients with unstable angina pectoris
    Akshay S Desai
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02120, USA
    Am J Cardiol 92:363-7. 2003
    ....
  76. ncbi request reprint Adjusting for unmeasured confounders in pharmacoepidemiologic claims data using external information: the example of COX2 inhibitors and myocardial infarction
    Sebastian Schneeweiss
    Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02120, USA
    Epidemiology 16:17-24. 2005
    ..We show how to assess the impact of confounding by factors not measured in Medicare claims data in a study of the association between selective COX2 inhibitors and acute myocardial infarction (MI)...
  77. ncbi request reprint Use of the case-crossover design to study prolonged drug exposures and insidious outcomes
    Philip S Wang
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Ann Epidemiol 14:296-303. 2004
    ..We investigated whether case-crossover methods can be used to study prolonged exposures and insidious outcomes...
  78. pmc Noncompliance with antihypertensive medications: the impact of depressive symptoms and psychosocial factors
    Philip S Wang
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School Boston, Mass 02115, USA
    J Gen Intern Med 17:504-11. 2002
    ..Addressing the epidemic of poor compliance with antihypertensive medications will require identifying factors associated with poor adherence, including modifiable psychosocial and behavioral characteristics of patients...
  79. ncbi request reprint Highlights and a hidden hazard--the FDA's new labeling regulations
    Jerry Avorn
    Harvard Medical School and Division of Pharmacoepidemiology and Pharmacoeconomics at Brigham and Women s Hospital, Boston, USA
    N Engl J Med 354:2409-11. 2006
  80. pmc Economic consequences of underuse of generic drugs: evidence from Medicaid and implications for prescription drug benefit plans
    Michael A Fischer
    Department of Medicine, Brigham and Women s Hospital, Boston, MA 02120, USA
    Health Serv Res 38:1051-63. 2003
    ..To calculate the financial impact of underuse of generic medications in state Medicaid programs...
  81. ncbi request reprint Dopamine antagonists and the development of breast cancer
    Philip S Wang
    Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital, 221 Longwood Ave, Boston, MA 02115, USA
    Arch Gen Psychiatry 59:1147-54. 2002
    ..Although animal studies have raised the possibility that prolactin-elevating dopamine antagonists used to treat psychotic disorders may initiate and promote breast cancers, epidemiologic studies in humans have been limited and inconsistent...
  82. ncbi request reprint Should clozapine continue to be restricted to third-line status for schizophrenia?: a decision-analytic model
    Philip S Wang
    Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital, 1620 Tremont Street, Suite 3030 Boston, MA 02120, USA
    J Ment Health Policy Econ 7:77-85. 2004
    ..Clozapine is currently restricted to patients who have failed at least two trials of other antipsychotic medications because of concerns that its use as a first-line agent would lead to greater mortality, mainly through agranulocytosis...
  83. ncbi request reprint Racial differences in screening for prostate cancer in the elderly
    Timothy Gilligan
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Arch Intern Med 164:1858-64. 2004
    ..Low screening rates among black men may contribute to these disparities, but there are few data on racial differences in prostate cancer screening...
  84. ncbi request reprint Clozapine use and risk of diabetes mellitus
    Philip S Wang
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    J Clin Psychopharmacol 22:236-43. 2002
    ..Additional data from pharmacoepidemiologic studies and randomized controlled trials are needed to exclude the possibility of residual confounding and ensure the appropriate use of this agent...
  85. ncbi request reprint Delayed nephrologist referral and inadequate vascular access in patients with advanced chronic kidney failure
    Jerry Avorn
    Division of Pharmacoepidemiology and Pharmacoeconomics, Division of Nephrology, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    J Clin Epidemiol 55:711-6. 2002
    ..17; 1.71)]. Inadequate development of vascular access for renal replacement therapy in patients with late nephrologist referral unnecessarily contributes to the burden of disease experienced by this vulnerable patient population...
  86. pmc Preventive health care measures before and after start of renal replacement therapy
    Wolfgang C Winkelmayer
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Mass 02115, USA
    J Gen Intern Med 17:588-95. 2002
    ..To describe utilization of preventive health care measures in patients with chronic kidney disease (CKD), both in the year prior to onset of renal replacement therapy (RRT), and in the first year of RRT...
  87. ncbi request reprint Underuse of osteoporosis medications in elderly patients with fractures
    Daniel H Solomon
    Division of Pharmacoepidemiology, Brigham and Women s Hospital, Boston, Massachusetts 02120, USA
    Am J Med 115:398-400. 2003
  88. ncbi request reprint Conversion from intravenous to oral medications: assessment of a computerized intervention for hospitalized patients
    Michael A Fischer
    Division of Pharmacoepidemiology and Pharmacoeconomics, Departments of Medicine and Emergency Medicine, Brigham and Women s Hospital, Harvard Medical School, 1620 Tremont Street, Suite 3030, Boston, MA 02120, USA
    Arch Intern Med 163:2585-9. 2003
    ..We examined the effect of a computer-based intervention to prompt physicians to switch appropriate patients from intravenous to oral medications...
  89. ncbi request reprint Which patients with knee problems are likely to benefit from nonarthroplasty surgery? Development of a clinical prediction rule
    Daniel H Solomon
    Division of Pharmacoepidemiology, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02120, USA
    Arch Intern Med 164:509-13. 2004
    ..We examined factors associated with the clinical presentation of patients judged likely by orthopedic surgeons to benefit from nonarthroplasty knee surgery...
  90. ncbi request reprint Nonsteroidal anti-inflammatory drug use and acute myocardial infarction
    Daniel H Solomon
    Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Arch Intern Med 162:1099-104. 2002
    ..Although aspirin has been shown to protect patients from acute myocardial infarction (AMI), the effect of nonaspirin nonsteroidal anti-inflammatory drugs (NSAIDs) is not clear...
  91. ncbi request reprint Economic implications of evidence-based prescribing for hypertension: can better care cost less?
    Michael A Fischer
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Mass 02120, USA
    JAMA 291:1850-6. 2004
    ..Suboptimal prescribing patterns contribute to the high cost of medications for elderly patients as well as the difficulty in providing affordable prescription drug benefits for older Americans...
  92. ncbi request reprint Pharmacoepidemiology and rheumatic diseases: 2001-2002
    Daniel H Solomon
    Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Curr Opin Rheumatol 15:122-6. 2003
    ....
  93. ncbi request reprint The hidden cost of nonselective nonsteroidal antiinflammatory drugs in older patients
    Daniel H Solomon
    Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    J Rheumatol 30:792-8. 2003
    ..We calculated the excess risk and costs associated with the major adverse effects of prescription nonselective NSAID...
  94. ncbi request reprint Kidney function and use of recommended medications after myocardial infarction in elderly patients
    Wolfgang C Winkelmayer
    Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital, 1620 Tremont Street, Suite 3030, Boston, MA 02120, USA
    Clin J Am Soc Nephrol 1:796-801. 2006
    ..Differences in other characteristics such as age, rather than kidney function, may be responsible for much or all the reported reduction in use of preventive medications after MI seen in patients with chronic kidney disease...
  95. ncbi request reprint Which patients with unstable angina or non-Q-wave myocardial infarction should have immediate cardiac catheterization? A clinical decision rule for predicting who will fail medical therapy
    Daniel H Solomon
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, 221 Longwood Avenue, Suite 341, Boston, MA 02115, USA
    J Clin Epidemiol 55:121-8. 2002
    ..Such a rule may be useful for identifying patients who should be considered for early cardiac catheterization...
  96. ncbi request reprint Strategies for the management of suspected heparin-induced thrombocytopenia: a cost-effectiveness analysis
    Amanda R Patrick
    Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham, Massachusetts 02120, USA
    Pharmacoeconomics 25:949-61. 2007
    ..Drugs used to treat HIT are costly and may carry an increased risk of bleeding...
  97. ncbi request reprint Nononcologic use of human recombinant erythropoietin therapy in hospitalized patients
    Michael A Fischer
    Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital, Harvard Medical School, Boston, Mass 02120, USA
    Arch Intern Med 167:840-6. 2007
    ..Little is known about the nature of rHuEPO use in hospitalized patients who receive rHuEPO therapy for nononcologic indications...
  98. ncbi request reprint Efficacy and safety of angiotensin II receptor blockade in elderly patients with diabetes
    Wolfgang C Winkelmayer
    Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital, Harvard Medical School, 1620 Tremont St, Suite 3030, Boston, MA 02120, USA
    Diabetes Care 29:2210-7. 2006
    ....
  99. ncbi request reprint Osteoporosis improvement: a large-scale randomized controlled trial of patient and primary care physician education
    Daniel H Solomon
    Division of Pharmacoepidemiology, Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts, USA
    J Bone Miner Res 22:1808-15. 2007
    ..04; 95% ci, 0.85-1.26)...
  100. ncbi request reprint The rise and fall of Natrecor for congestive heart failure: implications for drug policy
    Aaron S Kesselheim
    Harvard Medical School and Brigham and Women s Hospital, Boston, Massachusetts, USA
    Health Aff (Millwood) 25:1095-102. 2006
    ..Based on the nesiritide experience, we suggest several ways to improve policies for drug approval, postmarketing surveillance, and drug utilization...
  101. doi request reprint Osteoporosis medication use in nursing home patients with fractures in 1 US state
    Seema Parikh
    Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Womens Hospital, Harvard Medical School, Boston, MA 02120, USA
    Arch Intern Med 168:1111-5. 2008
    ..We studied the patterns and predictors of osteoporosis medication use in elderly patients who sustained a fracture and were admitted to an NH...